Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Retained Earnings (2023 - 2025)

Zenas BioPharma has reported Retained Earnings over the past 3 years, most recently at -$64000.0 for Q4 2025.

  • Quarterly results put Retained Earnings at -$64000.0 for Q4 2025, down 132.99% from a year ago — trailing twelve months through Dec 2025 was -$64000.0 (down 132.99% YoY), and the annual figure for FY2025 was -$64000.0, down 132.99%.
  • Retained Earnings for Q4 2025 was -$64000.0 at Zenas BioPharma, up from -$524.7 million in the prior quarter.
  • Over the last five years, Retained Earnings for ZBIO hit a ceiling of $194000.0 in Q4 2024 and a floor of -$524.7 million in Q3 2025.
  • Median Retained Earnings over the past 3 years was $37000.0 (2023), compared with a mean of -$142.5 million.
  • Biggest five-year swings in Retained Earnings: soared 424.32% in 2024 and later plummeted 971766.67% in 2025.
  • Zenas BioPharma's Retained Earnings stood at $37000.0 in 2023, then soared by 424.32% to $194000.0 in 2024, then plummeted by 132.99% to -$64000.0 in 2025.
  • The last three reported values for Retained Earnings were -$64000.0 (Q4 2025), -$524.7 million (Q3 2025), and -$473.2 million (Q2 2025) per Business Quant data.